Literature DB >> 16859776

Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome.

Georgios K Chalikias1, Dimitrios N Tziakas, Juan Carlos Kaski, Angelos Kekes, Eleni I Hatzinikolaou, Dimitrios A Stakos, Ioannis K Tentes, Alexandros X Kortsaris, Dimitrios I Hatseras.   

Abstract

BACKGROUND: The pro-inflammatory cytokine IL-18 has been suggested to play a role in atherogenesis and atheromatous plaque rupture leading to the acute coronary syndrome (ACS). Conversely, the anti-inflammatory cytokine IL-10 seems to have an atheroprotective role. Patients with unstable coronary artery disease show an imbalance between serum levels of pro- and anti-inflammatory cytokines, and studies have shown that IL-18/IL-10 ratio is an independent predictor of adverse in-hospital events in patients with ACS. We assessed the long-term prognostic significance of admission interleukin-18 (IL-18)/interleukin-10 (IL-10) ratio for recurrent coronary events during a 1-year follow-up in patients presenting with an ACS.
METHODS: We assessed independent predictors of the combined end-point using multiple logistic regression analysis, in 186 patients (138 men, 65+/-12 years) with ACS (75 STEMI, 65 NSTEMI and 46 unstable angina). The composite of cardiac death and re-hospitalization with non-fatal myocardial infarction, or unstable angina, was the pre-specified study end-point. Serum IL-10 and IL-18 levels were measured at study entry using commercially available ELISAs.
RESULTS: During the 1-year follow-up, 48 (26%) patients had recurrent cardiac events and 138 (74%) were event-free. IL-18/IL-10 ratio predicted the occurrence of adverse cardiac events (OR 1.91, 95% CI 1.37-2.65, p<0.001), and was found to be an independent predictor among other established biochemical and clinical risk markers (OR 2.31, 95% CI 1.55-3.42, p<0.001).
CONCLUSIONS: Serum IL-18/IL-10 ratio is an independent predictor of recurrent coronary events during long-term follow-up in patients presenting with ACS. Our study further supports the hypothesis that the balance between pro-inflammatory and anti-inflammatory cytokines may be an important determinant of patient outcome, suggesting a pathogenic role in plaque progression and instability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16859776     DOI: 10.1016/j.ijcard.2006.05.017

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.

Authors:  Huan-qin Chen; Hong-yong Tan; Yi-wen Yang; Lei Qiu; Xiang-qun Liu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

2.  Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure.

Authors:  Frederik H Verbrugge; Matthias Dupont; Zhili Shao; Kevin Shrestha; Dhssraj Singh; Michael Finucan; Wilfried Mullens; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09       Impact factor: 5.712

3.  The Association between Cytokines and 365-Day Readmission or Mortality in Adult Cardiac Surgery.

Authors:  Allen D Everett; Shama S Alam; Sherry L Owens; Devin M Parker; Christine Goodrich; Donald S Likosky; Heather Thiessen-Philbrook; Moritz Wyler von Ballmoos; Kevin Lobdell; Todd A MacKenzie; Jeffrey Jacobs; Chirag R Parikh; Anthony W DiScipio; David J Malenka; Jeremiah R Brown
Journal:  J Extra Corpor Technol       Date:  2019-12

Review 4.  Novel biomarkers for risk stratification and identification of life-threatening cardiovascular disease: troponin and beyond.

Authors:  Louai Razzouk; Mario Fusaro; Ricardo Esquitin
Journal:  Curr Cardiol Rev       Date:  2012-05

5.  The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI.

Authors:  Xin Wang; Xiangna Cai; Lan Chen; Duanmin Xu; Jilin Li
Journal:  Mediators Inflamm       Date:  2015-04-16       Impact factor: 4.711

6.  Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.

Authors:  Anna Severino; Chiara Zara; Mara Campioni; Davide Flego; Giulia Angelini; Daniela Pedicino; Ada Francesca Giglio; Francesco Trotta; Simona Giubilato; Vincenzo Pazzano; Claudia Lucci; Antonio Iaconelli; Aureliano Ruggio; Luigi Marzio Biasucci; Filippo Crea; Giovanna Liuzzo
Journal:  Oncotarget       Date:  2017-03-14

7.  Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review.

Authors:  Martin C Nwadiugwu
Journal:  Front Public Health       Date:  2021-01-25

8.  An IL-6-IL-8 score derived from principal component analysis is predictive of adverse outcome in acute myocardial infarction.

Authors:  Gisela A Kristono; Ana S Holley; Kathryn E Hally; Morgane M Brunton-O'Sullivan; Bijia Shi; Scott A Harding; Peter D Larsen
Journal:  Cytokine X       Date:  2020-10-08

9.  IL-6, IL-1RA and Resistin as Predictors of Left Ventricular Remodelling and Major Adverse Cardiac Events in Patients with Acute ST Elevation Myocardial Infarction.

Authors:  Alina Ioana Scărlătescu; Miruna Mihaela Micheu; Nicoleta Popa-Fotea; Ana Maria Pascal; Ana Maria Mihail; Ioana Petre; Silvia Deaconu; Aura Vîjîiac; Maria Dorobanțu
Journal:  Diagnostics (Basel)       Date:  2022-01-21

Review 10.  Association between inflammatory cytokines and long-term adverse outcomes in acute coronary syndromes: A systematic review.

Authors:  Gisela A Kristono; Ana S Holley; Prashant Lakshman; Morgane M Brunton-O'Sullivan; Scott A Harding; Peter D Larsen
Journal:  Heliyon       Date:  2020-04-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.